Meeting
2021 ASCO Annual Meeting
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.
Authors
Sara A. Hurvitz
University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA
Sara A. Hurvitz , Parvin F. Peddi , Merry L. Tetef , Nicholas Patrick McAndrew , Aashini K. Master , Maggie L. DiNome , Minna K Lee , Lisa S. Wang , Laura Spring , Christine Kivork , James Chauv , Aditya Bardia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04553770
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS603)
DOI
10.1200/JCO.2021.39.15_suppl.TPS603
Abstract #
TPS603
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
First Author: Sara A. Hurvitz
Poster
2018 ASCO Annual Meeting
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab ﴾HR+ with or without letrozole﴿ in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.
First Author: Patricia Villagrasa
Poster
2015 ASCO Annual Meeting
PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.
First Author: Patricia Villagrasa
Poster
2023 ASCO Annual Meeting
Racial disparities in utilization of first line targeted therapies for metastatic breast cancer.
First Author: Yehoda M. Martei